Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

116.23 +2.20 (+1.93%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2

...

16 17 18 19 20 21 22 23 Next >

Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2023 ↗

February 15, 2023

Via Benzinga

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results, Provide Corporate Update and Host Conference Call

February 14, 2023

From Corcept Therapeutics Incorporated

Via GlobeNewswire

Corcept Therapeutics Return On Capital Employed Overview ↗

August 11, 2022

Via Benzinga

Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation

February 13, 2023

From Corcept Therapeutics Incorporated

Via GlobeNewswire

EQUITY ALERT: Rosen Law Firm Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation – CORT

December 28, 2022

From The Rosen Law Firm, P.A.

Via Business Wire

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm

December 16, 2022

From The Schall Law Firm

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm

December 15, 2022

From The Schall Law Firm

Via Business Wire

5 Most Cheapest Stocks In The Healthcare Sector: Bio-Techne, Mirati Therapeutics And More ↗

December 15, 2022

The most oversold stocks in the healthcare sector presents an opportunity to buy into undervalued companies.

Via Benzinga

Our 7 Top Biotech Stock Picks for 2023 ↗

December 09, 2022

Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023.

Via InvestorPlace

Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals

December 08, 2022

From Corcept Therapeutics Incorporated

Via GlobeNewswire

Corcept Therapeutics Provides Miricorilant Clinical Development Update

December 08, 2022

From Corcept Therapeutics Incorporated

Via GlobeNewswire

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

November 03, 2022

From Corcept Therapeutics Incorporated

Via GlobeNewswire

Corcept Therapeutics's Earnings: A Preview ↗

November 02, 2022

Corcept Therapeutics (NASDAQ:CORT) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

October 27, 2022

From Corcept Therapeutics Incorporated

Via GlobeNewswire

These 3 Stocks Are Winning the Bear Market -- Here's How ↗

October 21, 2022

Picking the right markets to compete in makes surviving bear markets much more manageable for these companies.

Via The Motley Fool

7 Under-the-Radar Stocks With 100% Upside Potential ↗

October 17, 2022

If you're looking for under-the-radar stocks in the current market environment, you're likely to find many imposters so tread carefully.

Via InvestorPlace

Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)

October 11, 2022

From Corcept Therapeutics Incorporated

Via GlobeNewswire

Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings ↗

July 26, 2022

IBD 50 member Amphastar Pharmaceuticals stock is expected to report on Aug. 9 and is trading approximately 12% below a 42.41 entry.

Via Investor's Business Daily

Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5 ↗

July 15, 2022

The group has several commonalities, including strong ratings and promising charts.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2022 ↗

August 01, 2022

Upgrades

Via Benzinga

3 Biotech Stocks Outperforming a Bear Market ↗

July 15, 2022

These biotech stocks are the most attractive from a valuation and growth perspective as they are less impacted by a slowing economy or change in monetary policy.

Via InvestorPlace

Apellis Pharmaceuticals Stock Scores Relative Strength Rating Upgrade ↗

July 13, 2022

ApellisPharmaceuticals sees its Relative Strength Rating reach the elite 90-plus level.

Via Investor's Business Daily

Vir Biotechnology Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗

July 11, 2022

On Monday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 91 Monday, up from 85 a day earlier.

Via Investor's Business Daily

Uniqure Stock Sees Healthy Price Gain, Ranks Among Top 8% ↗

July 11, 2022

Among its other key ratings, Amsterdam-based gene therapy company Uniqure stock also has a 92 Composite Rating.

Via Investor's Business Daily

Kezar Life Sciences Stock Shows Rising Market Leadership: Earns 81 RS Rating ↗

July 08, 2022

The Relative Strength (RS) Rating for Kezar Life Sciences stock jumped into a new percentile Friday, with a rise from 78 to 81.

Via Investor's Business Daily

Apellis Pharmaceuticals Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗

July 08, 2022

Apellis Pharmaceuticals stock saw its Relative Strength (RS) Rating upgraded to 85 Friday, up from 79 a day earlier.

Via Investor's Business Daily

Global Blood Therapeutic Stock Sees Relative Strength Rating Rise To 91 ↗

July 05, 2022

Global Blood Therapeutic stock saw a positive improvement to its Relative Strength Rating on Tuesday, rising from 85 to 91.

Via Investor's Business Daily

Kura Oncology Stock Scores Rising Relative Strength ↗

June 30, 2022

On Thursday, Kura Oncology stock had its Relative Strength (RS) Rating stock upgraded to 93 from 81 a day earlier.

Via Investor's Business Daily

Syndax Pharmaceuticals Stock Sees RS Rating Rise To 92 ↗

June 30, 2022

Syndax Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 80 to 92.

Via Investor's Business Daily

The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial ↗

June 30, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

< Previous 1 2

...

16 17 18 19 20 21 22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.